8-K: Collegium Acquires AZSTARYS, Boosts ADHD Portfolio

Collegium Pharmaceutical will acquire AZSTARYS for $650 million in cash, strengthening its ADHD market position and accelerating growth.

Summary

• Collegium Pharmaceutical, Inc. (Collegium) has entered into an Equity Purchase Agreement to acquire AZSTARYS, a central nervous system stimulant prescription medicine for ADHD, from Corium Therapeutics Holdings, LLC and Corium, LLC (Seller Parties).
• The acquisition price is $650 million in cash at closing, with potential additional milestone payments of up to $135 million in aggregate cash based on future commercial and regulatory achievements.
• The transaction is expected to close in the second quarter of 2026, subject to customary closing conditions, including Hart-Scott-Rodino (HSR) approvals.
• AZSTARYS is protected by six Orange Book-listed patents, with most expiring in December 2037.
• The acquisition will be funded by Collegium's existing cash on hand and a $300 million delayed draw term loan, part of a syndicated credit facility announced in December 2025.
• The term loan will bear interest at an annual rate of SOFR plus a spread ranging from 2.75% to 3.75%, starting at SOFR plus 3.25% at closing.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this acquisition as a strong strategic move for Collegium, enhancing its market position in a growing therapeutic area with a differentiated product and clear financial benefits, including immediate accretion and significant synergies.

Positives

• The acquisition is expected to be immediately accretive to Collegium's adjusted EBITDA.
• AZSTARYS is projected to generate over $50 million in pro forma net revenue in the second half of 2026.
• Annual run rate synergies are anticipated to exceed $50 million within twelve months post-closing.
• The acquisition significantly strengthens Collegium's position in the ADHD market, adding a complementary and differentiated medicine to its portfolio.
• Patent protection for AZSTARYS extends into December 2037, providing long-term revenue longevity.
• The transaction leverages Collegium's existing ADHD commercial infrastructure and expertise, driving operational efficiencies and increased revenue scale.

Negatives

• Collegium may be required to pay a termination fee of $24 million under specified circumstances, such as a material breach of obligations leading to termination or failure to close by the Outside Date due to regulatory issues caused by a party's breach.

Risks

• Risks related to the ability to complete the transaction on proposed terms and schedule or at all.
• Failure or delay in receiving required regulatory approvals relating to the transaction.
• Inability to realize the anticipated benefits of the proposed acquisition, including the possibility that expected benefits will not be realized or not within the expected time period.
• Risk that the acquired businesses will not be integrated successfully.
• Disruption from the transaction making it more difficult to maintain business and operational relationships.
• Negative effects of the announcement or consummation of the proposed acquisition on the market price of common stock and/or operating results.
• Risks related to significant transaction costs or the acquisition of unknown liabilities.
• Risk of litigation and/or regulatory actions related to the proposed acquisition.
• Uncertainty of the expected financial performance of AZSTARYS and other products.
• Ability to commercialize and grow sales of products.
• Ability to manage relationships with licensors.
• Success of competing products that are or become available.
• Ability to obtain and maintain regulatory approval of products, and any related restrictions, limitations, and/or warnings in the label.
• Size of the markets for products and product candidates, and ability to service those markets.
• Ability to obtain reimbursement and third-party payor contracts for products.
• Rate and degree of market acceptance of products.
• Costs of commercialization activities, including marketing, sales and distribution.
• Changing market conditions for products.
• Outcome of any patent infringement, opioid-related or other litigation that may be brought by or against Collegium, including litigation with Purdue Pharma, L.P.
• Outcome of any governmental investigation related to Collegium's business.
• Ability to secure adequate supplies of active pharmaceutical ingredient for each product and manufacture adequate supplies of commercially saleable inventory.
• Ability to obtain funding for operations and business development.
• Regulatory developments in the U.S.
• Expectations regarding the ability to obtain and maintain sufficient intellectual property protection for products.
• Ability to comply with stringent U.S. and foreign government regulation in the manufacture of pharmaceutical products, including U.S. Drug Enforcement Agency compliance.
• Customer concentration.
• Accuracy of estimates regarding expenses, revenue, capital requirements and need for additional financing.

Future Outlook

Collegium expects the acquisition of AZSTARYS to significantly strengthen its ADHD portfolio, accelerate its growth trajectory, and extend revenue longevity into 2037 and beyond. The company anticipates immediate accretion to adjusted EBITDA and plans to rapidly pay down debt from future cash flows. Collegium will update its 2026 financial guidance upon the closing of the deal.

Management Comments

• Vikram Karnani, President and Chief Executive Officer, stated: 'The addition of AZSTARYS will significantly complement our existing ADHD business while extending revenues into 2037 and beyond. This immediately accretive transaction meaningfully advances our ambition to build a leading, diversified biopharmaceutical company.'
• Todd Smith, Chief Executive Officer of Corium Therapeutics, commented: 'We are proud of the progress that has been achieved and believe Collegium is well positioned to build on that foundation and continue expanding its reach.'

Industry Context

StockSavvy.ai notes that the U.S. ADHD market is large and growing, with an 8% CAGR from 2020-2025, and patients often try multiple treatments before finding an effective one. Stimulants remain the preferred treatment. This acquisition positions Collegium to capitalize on these trends by expanding its presence in a high-demand therapeutic area with a differentiated product, AZSTARYS, complementing its existing ADHD medicine, JORNAY PM.

Comparison to Industry Standards

• The filing highlights AZSTARYS's differentiation as the 'first and only ADHD treatment with both immediate release and long-acting medicines in one capsule,' which is a key competitive advantage.
• HCPs view both JORNAY PM and AZSTARYS as differentiated medicines, with 70% of surveyed HCPs indicating intent to increase prescribing of JORNAY PM and 53% for AZSTARYS, suggesting strong market acceptance for Collegium's ADHD portfolio.
• AZSTARYS generated over 760,000 prescriptions in 2025, indicating a significant market presence that Collegium aims to grow further by leveraging its commercial infrastructure, similar to how it manages JORNAY PM.

Legal Proceedings

• The filing notes risks related to litigation and/or regulatory actions concerning the proposed acquisition.
• Risks include potential patent infringement, opioid-related, or other litigation that may be brought by or against Collegium, specifically mentioning litigation with Purdue Pharma, L.P.
• There is also a risk of governmental investigations related to the business.

Related Party Transactions

• No Related Party (Affiliate, officer, director, or employee of Seller Parties or their Subsidiaries) has a material interest in any Person that purchases from or sells/licenses material goods, property, technology, or IP rights to the Azstarys Entities or Corium Seller (related to the Business).
• No Related Party is a party to a Material Contract (other than ordinary course employment contracts).
• No Related Party has initiated or threatened any Action against the Azstarys Entities or Corium Seller (related to the Business).
• No Related Party owes or is owed any Indebtedness by the Azstarys Entities or Corium Seller (related to the Business), except for ordinary course wages/expense reimbursements for officers/directors.
• No Related Party has engaged in any non-ordinary course transaction with the Azstarys Entities or Corium Seller (related to the Business).

Stakeholder Impact

• Shareholders: Expected to benefit from accelerated growth, increased revenue, margin expansion, enhanced cash flow generation, and immediate accretion to adjusted EBITDA, though there are risks to stock price and operating results from the transaction.
• Employees: Integration of businesses may lead to changes, but the filing mentions leveraging existing commercial infrastructure and expertise.
• Customers/Patients: The acquisition expands Collegium's ADHD portfolio with a differentiated medicine, potentially offering more treatment options and addressing unmet needs.
• Creditors: The company expects net leverage to be approximately 2x based on estimated 2026 combined adjusted EBITDA at deal close, with plans for rapid debt paydown, indicating a manageable debt profile.
• Suppliers: The filing mentions maintaining existing relations with key suppliers and manufacturers as a goal during the interim period.

Next Steps

• The transaction is expected to close in the second quarter of 2026.
• Collegium expects to update its 2026 financial guidance upon the closing of the deal.
• Collegium plans to rapidly pay down debt from future cash from operations.

Key Dates

Recommendation

The acquisition of AZSTARYS is a highly strategic move for Collegium Pharmaceutical, significantly strengthening its position in the growing ADHD market with a differentiated product that has long-term patent protection. The transaction is expected to be immediately accretive to adjusted EBITDA, generate substantial pro forma revenue in the near term, and create significant annual synergies. While there are integration and regulatory risks, the financial and strategic benefits outlined in the filing suggest a strong positive outlook for the company's growth and profitability, making it an attractive investment.

Keywords

ADHD treatment, AZSTARYS, Collegium Pharmaceutical, Corium Therapeutics, Acquisition, Biopharmaceutical, CNS stimulant, Pharmaceutical M&A, Drug development, Patent protection, Healthcare industry